MLICM
DFTX

Metropolitan Life Insurance Company (MetLife)’s Definium Therapeutics DFTX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,048
Closed -$17.5K – 2410
2022
Q1 		$17.5K Sell
1,048
-4,109
-80% -$71.3K ﹤0.01% 2146
2021
Q4 		$107K Buy
5,157
+427
+9% +$13.6K ﹤0.01% 2439
2021
Q3 		$165K Sell
4,730
-1,697
-26% -$73.4K ﹤0.01% 2216
2021
Q2 		$333K Buy
+6,427
New +$337K ﹤0.01% 1780

Other funds holding DFTX

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s DFTX Position: Q2 2022 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Definium Therapeutics (DFTX) in Q2 2022, closing a stake of 1,048 shares — an estimated $17.5K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in DFTX in Q2 2021 and held it in 4 quarters. The position peaked at $333K in Q2 2021. 155 funds tracked by Wall St. Rank hold DFTX as of Q2 2022.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Definium Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 1,048 Definium Therapeutics shares in Q2 2022, an estimated $17.5K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Definium Therapeutics in Q2 2021 and held it in 4 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Definium Therapeutics position peaked at $333K in Q2 2021.
  • 155 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2022.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2022, filed 11 Aug 2022.